BACKGROUND: The changes induced in host immunity and the tumor microenvironment by chemotherapy have been shown to impact immunotherapy response in both a positive and a negative fashion. Temozolomide is the most common chemotherapy used to treat glioblastoma (GBM) and has been shown to have variable effects on immune response to immunotherapy. Therefore, we aimed to determine the immune modulatory effects of temozolomide that would impact response to immune checkpoint inhibition in the treatment of experimental GBM. METHODS: Immune function and antitumor efficacy of immune checkpoint inhibition were tested after treatment with metronomic dose (MD) temozolomide (25 mg/kg × 10 days) or standard dose (SD) temozolomide (50 mg/kg × 5 days) in the GL261 and KR158 murine glioma models. RESULTS: SD temozolomide treatment resulted in an upregulation of markers of T-cell exhaustion such as LAG-3 and TIM-3 in lymphocytes which was not seen with MD temozolomide. When temozolomide treatment was combined with programmed cell death 1 (PD-1) antibody therapy, the MD temozolomide/PD-1 antibody group demonstrated a decrease in exhaustion markers in tumor infiltrating lymphocytes that was not observed in the SD temozolomide/PD-1 antibody group. Also, the survival advantage of PD-1 antibody therapy in a murine syngeneic intracranial glioma model was abrogated by adding SD temozolomide to treatment. However, when MD temozolomide was added to PD-1 inhibition, it preserved the survival benefit that was seen by PD-1 antibody therapy alone. CONCLUSION: The peripheral and intratumoral immune microenvironments are distinctively affected by dose modulation of temozolomide.
BACKGROUND: The changes induced in host immunity and the tumor microenvironment by chemotherapy have been shown to impact immunotherapy response in both a positive and a negative fashion. Temozolomide is the most common chemotherapy used to treat glioblastoma (GBM) and has been shown to have variable effects on immune response to immunotherapy. Therefore, we aimed to determine the immune modulatory effects of temozolomide that would impact response to immune checkpoint inhibition in the treatment of experimental GBM. METHODS: Immune function and antitumor efficacy of immune checkpoint inhibition were tested after treatment with metronomic dose (MD) temozolomide (25 mg/kg × 10 days) or standard dose (SD) temozolomide (50 mg/kg × 5 days) in the GL261 and KR158 murineglioma models. RESULTS:SD temozolomide treatment resulted in an upregulation of markers of T-cell exhaustion such as LAG-3 and TIM-3 in lymphocytes which was not seen with MD temozolomide. When temozolomide treatment was combined with programmed cell death 1 (PD-1) antibody therapy, the MD temozolomide/PD-1 antibody group demonstrated a decrease in exhaustion markers in tumor infiltrating lymphocytes that was not observed in the SD temozolomide/PD-1 antibody group. Also, the survival advantage of PD-1 antibody therapy in a murine syngeneic intracranial glioma model was abrogated by adding SD temozolomide to treatment. However, when MD temozolomide was added to PD-1 inhibition, it preserved the survival benefit that was seen by PD-1 antibody therapy alone. CONCLUSION: The peripheral and intratumoral immune microenvironments are distinctively affected by dose modulation of temozolomide.
Authors: Malte Mohme; Simon Schliffke; Cecile L Maire; Alessandra Rünger; Laura Glau; Klaus C Mende; Jakob Matschke; Christina Gehbauer; Nuray Akyüz; Svenja Zapf; Mareike Holz; Miriam Schaper; Tobias Martens; Nils O Schmidt; Sven Peine; Manfred Westphal; Mascha Binder; Eva Tolosa; Katrin Lamszus Journal: Clin Cancer Res Date: 2018-02-14 Impact factor: 12.531
Authors: Thomas Powles; Joseph Paul Eder; Gregg D Fine; Fadi S Braiteh; Yohann Loriot; Cristina Cruz; Joaquim Bellmunt; Howard A Burris; Daniel P Petrylak; Siew-leng Teng; Xiaodong Shen; Zachary Boyd; Priti S Hegde; Daniel S Chen; Nicholas J Vogelzang Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: John H Sampson; Kenneth D Aldape; Gary E Archer; April Coan; Annick Desjardins; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner; Amy B Heimberger Journal: Neuro Oncol Date: 2010-12-10 Impact factor: 12.300
Authors: E John Wherry; Sang-Jun Ha; Susan M Kaech; W Nicholas Haining; Surojit Sarkar; Vandana Kalia; Shruti Subramaniam; Joseph N Blattman; Daniel L Barber; Rafi Ahmed Journal: Immunity Date: 2007-10-18 Impact factor: 31.745
Authors: Ling Cen; Brett L Carlson; Jenny L Pokorny; Ann C Mladek; Patrick T Grogan; Mark A Schroeder; Paul A Decker; S Keith Anderson; Caterina Giannini; Wenting Wu; Karla V Ballman; Gaspar J Kitange; Jann N Sarkaria Journal: Neuro Oncol Date: 2013-03-10 Impact factor: 12.300
Authors: Luis Sanchez-Perez; Bryan D Choi; Elizabeth A Reap; Elias J Sayour; Pamela Norberg; Robert J Schmittling; Gerald E Archer; James E Herndon; Duane A Mitchell; Amy B Heimberger; Darell D Bigner; John H Sampson Journal: Cancer Immunol Immunother Date: 2013-04-17 Impact factor: 6.968
Authors: Jing Zeng; Alfred P See; Jillian Phallen; Christopher M Jackson; Zineb Belcaid; Jacob Ruzevick; Nicholas Durham; Christian Meyer; Timothy J Harris; Emilia Albesiano; Gustavo Pradilla; Eric Ford; John Wong; Hans-Joerg Hammers; Dimitris Mathios; Betty Tyler; Henry Brem; Phuoc T Tran; Drew Pardoll; Charles G Drake; Michael Lim Journal: Int J Radiat Oncol Biol Phys Date: 2013-02-22 Impact factor: 7.038
Authors: David A Reardon; Prafulla C Gokhale; Sarah R Klein; Keith L Ligon; Scott J Rodig; Shakti H Ramkissoon; Kristen L Jones; Amy Saur Conway; Xiaoyun Liao; Jun Zhou; Patrick Y Wen; Annick D Van Den Abbeele; F Stephen Hodi; Lei Qin; Nancy E Kohl; Arlene H Sharpe; Glenn Dranoff; Gordon J Freeman Journal: Cancer Immunol Res Date: 2015-11-06 Impact factor: 11.151
Authors: Carter M Suryadevara; Rupen Desai; Melissa L Abel; Katherine A Riccione; Kristen A Batich; Steven H Shen; Pakawat Chongsathidkiet; Patrick C Gedeon; Aladine A Elsamadicy; David J Snyder; James E Herndon; Patrick Healy; Gary E Archer; Bryan D Choi; Peter E Fecci; John H Sampson; Luis Sanchez-Perez Journal: Oncoimmunology Date: 2018-02-21 Impact factor: 8.110
Authors: Nicholas McGranahan; Andrew J S Furness; Rachel Rosenthal; Sofie Ramskov; Rikke Lyngaa; Sunil Kumar Saini; Mariam Jamal-Hanjani; Gareth A Wilson; Nicolai J Birkbak; Crispin T Hiley; Thomas B K Watkins; Seema Shafi; Nirupa Murugaesu; Richard Mitter; Ayse U Akarca; Joseph Linares; Teresa Marafioti; Jake Y Henry; Eliezer M Van Allen; Diana Miao; Bastian Schilling; Dirk Schadendorf; Levi A Garraway; Vladimir Makarov; Naiyer A Rizvi; Alexandra Snyder; Matthew D Hellmann; Taha Merghoub; Jedd D Wolchok; Sachet A Shukla; Catherine J Wu; Karl S Peggs; Timothy A Chan; Sine R Hadrup; Sergio A Quezada; Charles Swanton Journal: Science Date: 2016-03-03 Impact factor: 47.728
Authors: Maryam Rahman; W Gregory Sawyer; Scott Lindhorst; Loic P Deleyrolle; Jeffrey K Harrison; Aida Karachi; Farhad Dastmalchi; Joseph Flores-Toro; Duane A Mitchell; Michael Lim; Mark R Gilbert; David A Reardon Journal: Neuro Oncol Date: 2020-09-29 Impact factor: 12.300
Authors: Antonino C Tralongo; Roberto S Fratamico; Chiara Russo; Andrea Sbrana; Andrea Antonuzzo; Marco Danova Journal: Geriatrics (Basel) Date: 2021-04-15
Authors: Juri Kiyokawa; Yoichiro Kawamura; Shanawaz M Ghouse; Simge Acar; Erinç Barçın; Jordi Martínez-Quintanilla; Robert L Martuza; Ramon Alemany; Samuel D Rabkin; Khalid Shah; Hiroaki Wakimoto Journal: Clin Cancer Res Date: 2020-11-30 Impact factor: 13.801
Authors: John P Lynes; Anthony K Nwankwo; Hannah P Sur; Victoria E Sanchez; Kwadwo A Sarpong; Oluwatobi I Ariyo; Gifty A Dominah; Edjah K Nduom Journal: J Immunother Cancer Date: 2020-05 Impact factor: 13.751